Fridays vs LifeMD (2026): prices, structure, verdict

On tirzepatide, Fridays is cheaper: $359 versus $597 a month all-in — a $238 monthly gap, $2,856 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Fridays is cheaper: $175 versus $348 a month all-in — a $173 monthly gap, $2,076 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Fridays: the record, condensed

Start with the load-bearing figure: $359 a month, all-in, is what Fridays charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #13 of 17 verified programs, with the floor $144/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $90 a month. A year at this figure: $4,308 monthly-billed.

Start with the load-bearing figure: $175 a month, all-in, is what Fridays charges for semaglutide at the 2.4 mg basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $175 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #7 of 20 in the verified semaglutide index — $42/month above the floor (Oak Longevity, $133) — and sits $174 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $2,100.

Operationally at Fridays: shipping included; commitment annual plan for lowest rate; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Fridays page · visit Fridays ↗

LifeMD: the record, condensed

On tirzepatide, the number that matters at LifeMD is $597 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The all-in figure already contains a compulsory $149 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $448 would be exactly that kind of mirage.

To place the number: #17 of 17 verified programs, with the floor $382/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth nothing a month — at which point brand deserves the first look. A year at this figure: $7,164 monthly-billed.

LifeMD’s semaglutide program bills $348 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at LifeMD is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The all-in figure already contains a compulsory $149 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $199 would be exactly that kind of mirage.

Context for that figure: it ranks #20 of 20 in the verified semaglutide index — $215/month above the floor (Oak Longevity, $133) — and sits $1 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $4,176.

Operationally at LifeMD: shipping included; commitment program fee recurs monthly; cancellation program fee recurs until cancelled; pharmacy not publicly named — ask in writing before paying; states: 50 states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the LifeMD page · visit LifeMD ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: Fridays at $359, LifeMD at $597 — a $238 monthly spread that compounds to $2,856 over a maintenance year and $5,712 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $238 gap is exactly what it appears to be.

LifeMD’s total includes a mandatory $149/month membership; Fridays has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $175 (Fridays) against $348 (LifeMD). $173 a month sounds survivable; $2,076 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $173 gap is exactly what it appears to be.

LifeMD’s total includes a mandatory $149/month membership; Fridays has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

A way to feel the $238 monthly gap: over a year it funds 8.0 extra months at Fridays’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $5,712, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: Fridays $359/mo month-to-month against LifeMD $597/mo month-to-month. The order holds: Fridays leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Fridays $1,077 monthly; LifeMD $1,791 monthly — best path favors Fridays by $714. 6 months: Fridays $2,154 monthly; LifeMD $3,582 monthly — best path favors Fridays by $1,428. 12 months: Fridays $4,308 monthly; LifeMD $7,164 monthly — best path favors Fridays by $2,856. 24 months: Fridays $8,616 monthly; LifeMD $14,328 monthly — best path favors Fridays by $5,712.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Fridays $525 vs LifeMD $1,044 — $519 to Fridays. 6 mo: Fridays $1,050 vs LifeMD $2,088 — $1,038 to Fridays. 12 mo: Fridays $2,100 vs LifeMD $4,176 — $2,076 to Fridays. 24 mo: Fridays $4,200 vs LifeMD $8,352 — $4,152 to Fridays.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Fridays publishes “not published”; LifeMD publishes “50 states” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Fridays — annual plan for lowest rate; not published. LifeMD — program fee recurs monthly; program fee recurs until cancelled.

Insurance: only LifeMD does coverage work — decisive if there is any chance your plan covers a brand GLP-1, because a covered prescription beats both cash paths on this page.

Evidence: Fridays third-party reported (captured 2026-08-05); LifeMD third-party reported (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #13 and #17 of 17: between them lie 3 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #7 and #20 of 20: between them lie 12 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Fridays and LifeMD

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Fridays: not published; LifeMD: program fee recurs until cancelled) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings